Navegando por Palavras-chave "risedronate"
Agora exibindo 1 - 3 de 3
Resultados por página
Opções de Ordenação
- ItemSomente MetadadadosBone Mass Outcomes in Patients With Osteoporosis Treated With Risedronate After Alendronate Failure: a 12-Month Follow-Up Study(Elsevier Science Inc, 2017) Mendonca, Leonardo Teixeira [UNIFESP]; Pinheiro, Marcelo Medeiros [UNIFESP]; Szejnfeld, Vera Lucia [UNIFESP]; Castro, Charlles Heldan de Moura [UNIFESP]Oral bisphosphonates are the drugs most frequently used for the treatment of osteoporosis. Clinicians usually switch between these drugs in clinical practice based on differences in efficacy. We aim to investigate the reasons associated with switching between oral bisphosphonates and to evaluate bone mass response and the incidence of fractures 12 mo after the exchange in a cohort of patients with osteoporosis seen at a tertiary hospital. Patients with osteoporosis who switched between oral bisphosphonates between January 2007 and December 2014 were included. Bone mass measured by dual-energy X-ray absorptiometry and the incidence of fracture were evaluated. A total of 112 patients (73.1 yr old on average, 95.5% women, 98% postmenopausal) were included. All patients were taking alendronate at the time of the switch to risedronate. In 91 patients (81.3%), the following reasons for the exchange of medication were identified: bone loss (59.8%), adverse events (11.6%), and recent fragility fracture (10.7%). One year after the switch, bone densitometry revealed bone loss in 51 patients (45.5%), bone mass maintenance in 34 (30.4%), and bone mass gain in 27 (24.1%). No new vertebral fracture was detected and no nonvertebral fracture was reported in 12 mo of follow-up. Bone mass outcomes (gain, loss, or maintenance) were not associated with the reason for switching between oral bisphosphonates. Similarly, none of the parameters evaluated could predict good densitometric response (gain or maintenance) in this scenario. Our findings suggest that the use of risedronate should not be recommended in the scenario of treatment failure or adverse events following the use of alendronate.
- ItemSomente MetadadadosEfeito do risedronato sobre a densidade mineral óssea de pacientes ambulatoriais com osteoporose previamente tratados com alendronato(Universidade Federal de São Paulo (UNIFESP), 2016-12-08) Mendonca, Leonardo Teixeira de [UNIFESP]; Castro, Charlles Heldan de Moura Castro [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)Introduction: Osteoporosis is the most common bone metabolic disease. There is no evidence of difference in efficacy between oral bisphosphonates. On the other hand, the exchange of a drug by another is common in clinical practice. Objectives: To investigate the reasons associated with switching between oral bisphosphonates and evaluate the response of bone mass and the incidence of vertebral and non-vertebral fracture 12 months after the exchange of medication. Methods: Patients with osteoporosis who have made the exchange of bisphosphonates (alendronate and risedronate) between January 1990 and December 2014 were included in the present study. Data on bone mass measured by DXA and fracture prevalence have been reported. Results: A total of 112 patients were included and most of them were women (95.5%). Mean age was 73.1 years and average time of diagnosis was 13.1 years. About 98% of the women were postmenopausal. All patients were taking Alendronate at the time of exchange for Risedronate. In 91 patients (81.3%) a reason for the exchange of medication was identified: bone loss (59.8%), adverse events (11.6% - mainly gastrointestinal events in 92.3%) and fracture in 10.7%. One year after the exchange, bone densitometry revealed bone loss in 51 patients (45.5%), bone mass maintenance in 34 (30.4%) and bone mass gain in 27 (24.1%). The reason for the exchange between bisphosphonates did not associate with bone mass outcome (gain, loss or maintenance). Similarly, none of the parameters evaluated in this study was predictor of good densitometric response (gain or maintenance). Conclusions: Our findings suggest that the use of risedronate should not be recommended in the scenario of treatment failure or in the presence of adverse events associated with the use of alendronate.
- ItemSomente MetadadadosEffects of Short-Term Risedronate on Bone Resorption and Patient Satisfaction in Postmenopausal Osteoporosis Patients(Elsevier B.V., 2009-01-01) Fernandes, Cesar E.; Zerbini, Cristiano; Russo, Luis A.; Albernaz, Marco A.; Eis, Sergi R.; Szejnfeld, Vera L. [UNIFESP]; Pompei, Luciano M.; Fac Med ABC; Hosp Heliopolis São Paulo; CCBR Brasil Ctr Anal & Pesquisas Clin; Hosp Materno Infantil Goiania; Ctr Diagnost & Pesquisa Osteoporose Espirito Sant; Universidade Federal de São Paulo (UNIFESP)This multicenter. open-label study evaluated the effects of short-term risedronate on bone resorption and patient satisfaction in postmenopausal women with osteoporosis in Brazil. Entry requirements included: osteoporosis of the spine/femoral neck diagnosed by a bone mineral density (BMD) T-score <= -2.5 or radiographic fragility fracture within the last year and no treatment with osteoporosis medication in the preceding 3 mo. Patients were treated with once weekly risedronate of 35 mg for 12 wk. Patients also received 1000 mg calcium carbonate and 400 IU vitamin D. the main outcome was the effect on bone resorption, as assessed by the quantification of serum C-telopeptide of type I collagen (CTX). of the 556 women screened, 480 women received >= 1 dose of study drug (intent-to-treat [ITT] population), and 390 completed treatment (81%). After 12 wk, CTX decreased in 94% of patients (from 0.419 +/- 0.234 to 0.158 +/- 0.171 mu g/L, p < 0.0001). Mean CTX reduction was 60.6%. Patient satisfaction was good/excellent in 91.7% of patients. A total of 156 adverse events (AEs) were reported by 113 (23.5%) patients in the ITT population. Digestive symptoms emerged or worsened in 7.1% and 3.5%. respectively. Five patients (1.0%) experienced serious AEs, not considered to be related to risedronate. in conclusion, risedronate significantly reduced scrum CTX after 12-wk treatment. Almost all patients reported good/excellent satisfaction.